Jiawei (Jerry) Wang
QLGNAbout Jiawei (Jerry) Wang
Jiawei (Jerry) Wang, age 34, was appointed Co‑Chief Executive Officer of Qualigen Therapeutics (QLGN) effective October 2, 2025 . He is Global President and an original founding team member of Faraday Future, where he was involved in strategic development since 2014, successfully raising more than $3 billion and leading the company’s IPO in 2021 . Wang previously served in capital markets leadership roles at Faraday Future (2017–2022), co‑founded AIBOT Inc. (AI‑driven eVTOL), and held corporate development and investment roles at Le Holdings, Global Galaxy, and Knights Investment Group . Recent filings do not disclose his education, TSR or company performance metrics tied to his role at QLGN .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Faraday Future Intelligent Electric Inc. | Vice President, Global Capital Markets | May 2018 – Apr 2022 | Led capital markets activities; part of team that raised >$3B and executed 2021 IPO |
| Faraday Future Intelligent Electric Inc. | Global Head of Capital Markets | Jan 2018 – May 2018 | Supported funding strategy during scale‑up |
| Faraday Future Intelligent Electric Inc. | General Manager, China Capital Markets | Mar 2017 – Jan 2018 | Advanced China capital markets engagement |
| Le Holdings Co. Ltd. | Director of Corporate Development | 2015 – 2017 | Corporate development initiatives |
| Global Galaxy Inc. | Co‑Founder | Sep 2013 – (start) | Private investment firm founder |
| Knights Investment Group | Private Equity Analyst | Dec 2013 – Feb 2014 | Buy‑side analytical support |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Faraday Future Intelligent Electric Inc. | Global President; founding team | 2014 – present | Raised >$3B and led 2021 IPO |
| AIBOT Inc. | Executive Chairman; now Chairman | Sep 2022 – Mar 2025; Chairman thereafter | AI‑driven intelligent eVTOL development |
Fixed Compensation
- As of appointment, “there are no compensation arrangements, plans, or agreements entered into between the Company and the newly appointed officers,” so base salary, target bonus, and equity grants for Wang have not been disclosed .
Performance Compensation
- The 2025 Equity Incentive Plan was approved by the Board (subject to stockholder approval), with a large equity pool and evergreen features designed to align pay with long‑term value creation; individual performance metrics and incentive weightings for Wang are not disclosed .
2025 Equity Incentive Plan Key Terms
| Item | Detail |
|---|---|
| Share reserve | Shares available equal to 20% of common stock outstanding following the Offering |
| Evergreen | Automatic annual increase on January 1 of each year of 10% of total common shares outstanding as of prior December 31, through 2046, unless Board sets a lesser amount |
| Administration | Compensation Committee or Board; includes grants to officers, directors, employees, consultants |
| Change‑in‑Control mechanics | Board may accelerate vesting, deem performance measures satisfied, or substitute successor securities/property; adjustments governed by Section 409A and Plan Sections 5.7–5.8 |
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Shares outstanding (record date) | 2,659,133 common shares as of September 22, 2025 |
| Jiawei Wang beneficial ownership | Less than 1% of common stock; specific share count not disclosed in the table |
| Ownership guidelines / pledging | Not disclosed in current filings |
Employment Terms
| Term | Detail |
|---|---|
| Title | Co‑Chief Executive Officer, effective October 2, 2025 |
| Reporting & scope | Reports to Board alongside current CEO; sole responsibility for all business operations including crypto‑related businesses, except medical‑related business |
| Controls | Sole access to all crypto‑related accounts of the Company |
| Appointment driver | Required by Lead Investor Agreement tied to September 19, 2025 financing |
| Compensation agreement | No compensation arrangements entered into at appointment |
| Change‑in‑control | Equity award acceleration governed by the 2025 Plan; Board discretion to accelerate/lapse restrictions or deem performance satisfied |
Investment Implications
- Alignment and retention: With less than 1% beneficial ownership and no disclosed CEO compensation package at appointment, alignment and retention incentives appear to be in flux pending formal compensation agreements; near‑term comp negotiation is a watch item for pay‑for‑performance alignment .
- Dilution and incentive design: The 2025 Equity Incentive Plan’s 20% initial pool and 10% annual evergreen through 2046 materially expand equity capacity, raising dilution risk but enabling performance‑based grants; monitoring grant sizes, vesting, and performance conditions for Wang will be critical .
- Governance/control dynamics: The Lead Investor Agreement imposes structural terms including Wang’s appointment and exclusive control over crypto accounts, indicating investor‑driven governance levers and operational centralization—both opportunities and concentration risks to assess .
- Execution track record: Wang’s prior role in raising >$3B and leading an IPO suggests capital markets capability suited to QLGN’s strategic pivot and financing needs; translating that experience into operating KPIs at QLGN remains to be evidenced in filings .
Monitoring priorities: finalize CEO compensation terms and performance metrics; Form 3/4 filings and any RSU/option grants; equity award vesting schedules under the 2025 Plan; changes to governance and committee oversight; and any disclosures on pledging, clawbacks, or change‑of‑control provisions specific to Wang .